GlassScriptPhysician profile
Adrian Secheresiu
NPI 1861473415
$4,741.55
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $1,172 · 2021: $1,069 · 2022: $774 · 2023: $751 · 2024: $49.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $915.67 | 2019-2024 | Breztri, Tagrisso, Farxiga |
| Amgen INC. | $630.81 | 2019-2023 | Otezla, Repatha |
| Pfizer INC. | $622.90 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $420.71 | 2019-2023 | Eliquis, Camzyos |
| Novo Nordisk INC | $338.11 | 2019-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $223.34 | 2019-2021 | |
| Amarin Pharma, INC. | $221.25 | 2020-2021 | |
| Abbvie INC. | $178.57 | 2019-2023 | Ubrelvy, Qulipta, Synthroid |
| Glaxosmithkline, LLC. | $168.41 | 2020-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $154.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $132.01 | 2019-2023 | |
| Lilly USA, LLC | $130.83 | 2019-2023 | Jardiance |
| Inspire Medical Systems, INC. | $73.65 | 2023 | Inspire |
| Exact Sciences Corporation | $72.74 | 2023-2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $53.78 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $48.47 | 2020-2021 | |
| Philips North America LLC | $40.42 | 2023 | |
| Nestle Healthcare Nutrition INC. | $37.50 | 2021 | |
| Genentech USA, INC. | $34.39 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $30.53 | 2019 | |
| Abbott Laboratories | $29.90 | 2022 | |
| Alexion Pharmaceuticals, INC. | $28.01 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.58 | 2020-2022 | |
| Optinose US, INC. | $26.15 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $25.82 | 2023 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.87 | 2023 | Jardiance, Tradjenta |
| Axonics, INC. | $16.76 | 2023 | Axonics |
| Biohaven Pharmaceutical Holding Company LTD. | $13.60 | 2022 | |
| Shionogi INC | $12.96 | 2019 | |
| Astellas Pharma US INC | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Secheresiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.